Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR...

eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster...

eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer SAN DIEGO, Oct. 04, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has...

Commence Bio to Present at 2016 Cell & Gene Meeting on the Mesa SPARKS, MD--(Marketwired - September 28, 2016) - Commence Bio, Inc., a biotechnology company focused on developing breakthrough immunotherapies using its proprietary STaRT™ platform, announced today...